Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis

• Published in: BMC cancer Vol. 21; no. 1; pp. 1 - 924
• Main Authors: Yamaguchi, Teppei, Shimizu, Junichi, Hasegawa, Takaaki, Horio, Yoshitsugu, Inaba, Yoshitaka, Hanai, Nobuhiro, Muro, Kei, Hida, Toyoaki
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 16-08-2021; BioMed Central; BMC
• Subjects: Adverse events; Apoptosis; Bacterial pneumonia; Chemotherapy; Chest; Chronic obstructive pulmonary disease; Clinical trials; Complications and side effects; Computed tomography; Development and progression; Diagnosis; Gastric cancer; Head & neck cancer; Head and neck cancer; Immune checkpoint inhibitors; Immunotherapy; Lung cancer; Lung diseases; Lung diseases, Interstitial; Monoclonal antibodies; Nivolumab; Non-small cell lung cancer; Non-small cell lung carcinoma; Patients; PD-1; PD-1 protein; Pneumonia; Pneumonitis; Radiation therapy; Regression analysis; Risk factors; Sex ratio; Small cell lung carcinoma; Smoking; Solid tumors; Targeted cancer therapy; Thorax; Tumors; Japan
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-021-08661-3

Background Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, has shown survival benefit in clinical trials of various malignant tumors. Nivolumab-induced pneumonitis is major immune-related adverse event (irAE) that is occasionally serious and life-threatening. The aim of this study was to examine the association between pre-existing interstitial lung disease (ILD) on chest computed tomography (CT) and nivolumab-induced pneumonitis among different types of solid tumors. Methods We retrospectively collected the clinical data of 311 patients who were diagnosed with non-small cell lung cancer (NSCLC), head and neck cancer (HNC), or gastric cancer (GC), and treated with nivolumab monotherapy. Patients who underwent chest CT immediately before starting nivolumab without previous thoracic radiotherapy or other immune checkpoint inhibitors were eligible. We collected baseline patient characteristics and assessed pre-existing ILD on baseline chest CT. Results Finally, 188 patients were included in the analysis: 96 patients with NSCLC, 43 patients with HNC, and 49 patients with GC. NSCLC patients had a significantly higher rate of pre-existing ILD compared with HNC/GC patients (P = 0.047). Nivolumab-induced pneumonitis occurred in 11.7% (22 of 188), including 14.6% (14 of 96) of NSCLC, and 8.7% (8 of 92) of HNC/GC. Univariate and multivariate logistic regression analyses revealed that pre-existing ILD (odds ratio, 5.92; 95% confidence interval (CI), 2.07-18.54, P = 0.0008) and male sex (odds ratio, 5.58; 95% CI, 1.01-104.40, P = 0.049) significantly increased the risk of nivolumab-induced pneumonitis. Conclusion Our results indicated that pre-existing ILD and male sex are risk factors for nivolumab-induced pneumonitis in solid tumors. Keywords: Non-small cell lung cancer, Head and neck cancer, Gastric cancer, Pneumonitis, Nivolumab, PD-1